Extendicare (TSE:EXE - Get Free Report) was upgraded by stock analysts at Cibc World Mkts to a "strong-buy" rating in a research report issued to clients and investors on Monday,Zacks.com reports.
A number of other equities research analysts have also recently weighed in on EXE. National Bank Financial upgraded Extendicare to a "strong-buy" rating in a research note on Wednesday, July 16th. CIBC set a C$18.00 price target on Extendicare and gave the company an "outperform" rating in a research note on Monday. Finally, National Bankshares increased their price target on Extendicare from C$15.45 to C$16.10 and gave the company an "outperform" rating in a research note on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Extendicare currently has a consensus rating of "Moderate Buy" and an average price target of C$14.92.
Get Our Latest Report on Extendicare
Extendicare Stock Down 0.2%
EXE opened at C$14.25 on Monday. Extendicare has a 1-year low of C$8.96 and a 1-year high of C$15.24. The stock's fifty day simple moving average is C$13.08 and its 200 day simple moving average is C$13.46. The company has a current ratio of 0.62, a quick ratio of 0.98 and a debt-to-equity ratio of 283.02. The stock has a market cap of C$1.19 billion, a PE ratio of 14.77 and a beta of 0.85.
About Extendicare
(
Get Free Report)
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Extendicare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.
While Extendicare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.